Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Long-Term Investments: 2019-2024

Historic Long-Term Investments for Intellia Therapeutics (NTLA) over the last 6 years, with Dec 2024 value amounting to $260.2 million.

  • Intellia Therapeutics' Long-Term Investments fell 44.58% to $158.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.8 million, marking a year-over-year decrease of 44.58%. This contributed to the annual value of $260.2 million for FY2024, which is 160.57% up from last year.
  • Latest data reveals that Intellia Therapeutics reported Long-Term Investments of $260.2 million as of FY2024, which was up 160.57% from $99.9 million recorded in FY2023.
  • Intellia Therapeutics' Long-Term Investments' 5-year high stood at $337.4 million during FY2021, with a 5-year trough of $4.7 million in FY2020.
  • For the 3-year period, Intellia Therapeutics' Long-Term Investments averaged around $143.1 million, with its median value being $99.9 million (2023).
  • As far as peak fluctuations go, Intellia Therapeutics' Long-Term Investments skyrocketed by 7,005.33% in 2021, and later crashed by 79.45% in 2022.
  • Intellia Therapeutics' Long-Term Investments (Yearly) stood at $4.7 million in 2020, then surged by 7,005.33% to $337.4 million in 2021, then crashed by 79.45% to $69.3 million in 2022, then surged by 44.02% to $99.9 million in 2023, then surged by 160.57% to $260.2 million in 2024.